Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population

Clinica Chimica Acta

Volumn 413, Issue 19-20, 2012, Pages 1605-1611

  Hsieh, Li Ling ^a,b   Er, Tze Kiong ^a,b   Chen, Chih Chieh ^c   Hsieh, Jan Sing ^a   Chang, Jan Gowth ^a,b   Liu, Ta Chih ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

BRAF gene; Colorectal cancer; Direct sequencing; High resolution melting; KRAS gene; PIK3CA gene

Indexed keywords

B RAF KINASE; DNA; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN;

ARTICLE; BRAF GENE; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; ETHNIC GROUP; EXON; FEASIBILITY STUDY; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC SCREENING; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; PIK3CA GENE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TAIWANESE;

ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; COLORECTAL NEOPLASMS; EXONS; HISTOCYTOCHEMISTRY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NUCLEIC ACID DENATURATION; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PREVALENCE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SEQUENCE ANALYSIS, DNA; TAIWAN;

EID: 84864390143     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.029     Document Type: Article

References (43)

1. Jemal A., Bray, Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Department of Health Health and vital statistics 2007, Department of Health, Executive Yuan, Taipei.
3. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
4. Chang D.Z., Kumar V., Ma Y., et al. Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2009, 22:2-18.
5. Fearon E.R., Volgelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
6. Park J.H., Kim I.J., Kang H.C., et al. Oligonucleotide microarray-based mutation detection of the K-ras gene in colorectal cancers with use of competitive DNA hybridization. Clin Chem 2004, 50:1688-1691.
7. Er T.K., Chang Y.S., Yeh K.T., et al. Comparison of two different methods for the screening of KRAS mutation in colorectal cancer. Clin Lab 2010, 56:175-186.
8. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351:289-305.
9. Roth A.D., Tejpar S., Delorenzi M., et al. Prognostic role of KRAS and BRAF in stage II and II resected colon cancer: result of the translational study on the PETACC-3, EORTC 40933, SAKK 60-00 trial. J Clin Oncol 2010, 28:466-474.
10. Minoo P., Moyer M.P., Jass J.R. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J Pathol 2007, 212:124-133.
11. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in the chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
12. Laurent-Puig P., Cayre A., Manceau G., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy with wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 27:5924-5930.
13. Markman B., Atzori F., Perez-Garcia H., et al. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2010, 21:683-691.
14. Karakas B., Bachman K.E., Park B.H. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006, 94:455-459.
15. Samuels Y., Ericson K. Oncogenic PI3K and its role in cancer. Curr Opin Oncol 2006, 18:77-82.
16. Nosho K., Kawasaki T., Ohnishi, et al. PIK3CA mutation in colorectal cancer: relationship with generic and epigenetic alterations. Neoplasia 2008, 10:534-541.
17. Barault L., Veyrie N., Jooste V., et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH-kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 2008, 122:2255-2259.
18. Chang C.C., Lin P.C., Lin C.H., et al. Rapid identification of CYP2C8 polymorphism by high resolution melting analysis. Clin Chim Acta 2012, 413:298-302.
19. Lin Y.C., Lin Y.C., Liu T.C., et al. High-resolution melting curve (HRM) analysis to establish CYP21A2 mutations converted from the CYP21A1P in congenital adrenal hyperplasia. Clin Chim Acta 2011, 412:1918-1923.
20. Reed G.H., Wittwer C.T. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 2004, 50:1748-1754.
21. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:57-61.
22. Faller M.B., Legrain M., Voegeli A.C., et al. Detection of K-Ras mutations in tumor samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer 2009, 100:985-992.
23. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634. [Di].
24. Di Nicolantonio F., Martini M., Molinari F., et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008, 26:5705-5712.
25. Borràs E., Jurado I., Hernan I., et al. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 2011, 11:406.
26. Herreros-Villanueva M., Rodrigo M., Claver M., et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011, 38:1315-1320.
27. Simi L., Pratesi N., Vignoli M., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253.
28. Saridaki Z., Tzardi M., Papadaki C., et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2nd line cetuximab-based therapy of colorectal cancer patients. PLoS One 2011, 26:e15980.
29. Li H.T., Lu Y.Y., An Y.X., et al. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer. Oncol Rep 2011, 25:1691-1697.
30. Kwon M.J., Lee S.E., Kang S.Y., et al. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nuclei acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011, 207:762-768.
31. Liou J.M., Wu M.S., Shun C.T., et al. Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis 2011, 26:1387-1395.
32. Sartore-Bianchi A., Martini M., Molinari F., et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857.
33. Prenen H., De S.J., Jacobs B., De R.W., et al. PIK3CA mutations are not major determination of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009, 15:3184-3188.
34. Ogino S., Nosho K., Kirkner G.J., et al. PIK3CA mutation is associated with poor prognosis among patients with curativelt resected colon cancer. J Clin Oncol 2009, 27:1477-1484.
35. Lin J.K., Lin A.J., Lin C.C., et al. The status of EGFR-associated genes could predict the outcome and tumor response of chemo-refractory metastatic colorectal patients using cetuximab and chemotherapy. J Surg Oncol 2011, 104:661-666.
36. Thomas R.K., Baker A.C., Debiasi R.M., et al. Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling. Oncogene 2000, 19:5367-5376.
37. Baldus S.E., Schaefer K.L., Engers R., et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010, 16:790-799.
38. Berman H.M., Westbrook J., Feng Z., et al. The Protein Data Bank. Nucleic Acids Res 2000, 28:235-242.
39. Wan P.T., Garnett M.J., Roe S.M., et al. Mechanisms of activation of the RAF-ERK signaling pathway by oncogenic mutation of B-RAF. Cell 2004, 116:855-867.
40. Sali A., Blundell T.L. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 1993, 234:779-815.
41. Huang C.H., Mandelker D., Schmidt-Kittler O., et al. The structure of a human p110α/p85α complex elucidates the effects of oncogenic PI3Kα mutations. Science 2007, 318:1744-1748.
42. Samuels Y., Wang Z., Bardelli A., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
43. Miled N., Yan Y., Hon W.C., et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317:239-242.